Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!
- – – > > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – ´´My´´ Dissertation #Innovation #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World
The influence of physical activity in the progression of experimental lung cancer in mice
- PMID: 22683274
- DOI: 10.1016/j.prp.2012.04.006
GRUPO_AF1 – GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO AFAN 1 – GROUP AFAN1 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO_AF2 – GROUP AFA2 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO AFAN 2 – GROUP AFAN 2 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
Slides – mestrado – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
DMBA CARCINOGEN IN EXPERIMENTAL MODELS
Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.
Copyright © 2012 Elsevier GmbH. All rights reserved.Mestrado – ´´My´´ Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – Faculty of Medicine of Sao Jose do Rio Preto BaixarRedefine Statistical SignificanceBaixar
´´We propose to change the default P-value threshold for statistical significance from 0.05 to 0.005 for claims of new discoveries.´´ https://www.nature.com/articles/s41562-017-0189-z Published: Daniel J. Benjamin, James O. Berger, […]Valen E. Johnson Nature Human Behaviour volume 2, pages6–10 (2018)
´´My´´ Monografia – Monograph – Induction of benznidazole resistance in human Trypanosoma cruzi isolates – Indução de resistência ao benzonidazol em isolados humanos de Trypanosoma cruzi – UFTM – Federal University of Triangulo Mineiro – Uberaba
LISTA DE NOMES DE PESSOAS QUE ME DERAM FEEDBACK POSITIVO SOBRE A LISTA DE EMAILS QUE FIZ EM 2015 (PROJETO) – PEOPLE´S NAMES (POSITIVE FEEDBACK ABOUT THE EMAIL LIST I DID IN 2015) – E-MAIL LIST – LISTA DE E-MAILS – PROJECT – PESQUISA -RESEARCH
My Facebook Page: http://www.facebook.com/scientificblog
Curriculum Lattes: http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4240145A2
E-mails Accounts: email@example.com firstname.lastname@example.org
YouTube Channel: https://www.youtube.com/channel/UC9gsWVbGYWO04iYO2TMrP8Q
Biograph – Dr. Rasu Shrestha – https://t.co/gMmol8tn2Y?amp=1
2nd International Conference on Immunity and Immunochemistry
Treating Covid-19 through Immune Based Therapies
AUG 09-10, 2021
“As we all know the Coronavirus disease 2019 (COVID-19) pandemic, brought about by extreme intense respiratory disorder Coronavirus 2 (SARS-CoV-2) has influenced a huge number of individuals around the world, touching off an unprecedented effort from mainstream researchers to comprehend the organic supporting of COVID19 pathophysiology. The immune system ensures against infections and sicknesses and produces antibodies to kill microbes.”
We’re delighted to welcome you to the 2nd International Conference on Immunity and Immunochemistry, taking place on August 09-10, 2021 in Barcelona, Spain. This event takes place over 2 days and will comprise plenary lectures, parallel sessions, poster sessions and our ever-popular ‘Workshop’ events, with something to suit all immunological and vaccines research. About the Conference
Immunochemistry 2021 gives a profound impulse into the most recent discoveries and innovative headway in the field of Immunity and Immunochemistry. With individuals from around the globe focused in on finding out about Immunology and its advances; this is your best opportunity to arrive at the biggest array of members from the Immunology community. Widely acclaimed speakers, the latest strategies, advancements, and the most up to date refreshes in Immunology are signs of this gathering. The aim of the event is to host shows from far-famed specialists across the planet to harness the new collaborations in medical specialty, and medical specialty Sciences. Therefore, researchers within the relevant field will gift their analysis to debate the new results. rising sessions includes, young researchers forum and poster sessions providing likelihood to young participants to develop their career. Through the oral and poster displays, scientific sessions, and networking sessions, we tend to encourage dialogue between all the attendees to fill within the gaps to inspire innovative collaborations.
- Immunologists, Virologists, Microbiologists
- Allergists, Pathologists, Biotechnologists
- Physicians and Infectious diseases treatment doctors
- University Professors
- Research Labs
- Various Societies Members
- Research Scholars and Medical Students
- Business Entrepreneurs
- Manufacturing Medical Devices and Pharma Companies
- Laboratory Technicians
Why to attend?
The attendees will notice exclusive sessions and panel discussions on the most recent innovations in Molecular medical specialty & Immunogenetics, be the first to showcase your analysis, innovation.
- Lectures from noted speakers
- Keynote forums by outstanding Professors and Directors
- Open Innovation Challenges
- Poster displays by Young Researchers
- Global Networking sessions with 50+ Countries
- Strengthening the network between the university, hospitals, research labs and pharma industries.
- Summarize the studies of Immune System and targeting therapies to prevent coronavirus disease.
- Discussing the latest findings and achievements in the treatment of Covid-19 through immunotherapies.
Global Immune Health Supplements Market was valued at US$ 14.1 Bn in 2019 and is expected to reach US$ 24.7 Bn by 2027, at a CAGR of 7.26% during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market; same will help decision makers to prepare the outline for short term and long term strategies for companies by region.
The global immune health supplements market is driven by the increased awareness regarding the benefits of the immune health supplements among consumers. Increasing consumption of immune health supplements around the globe, which is anticipated to drive the immune health supplements market growth in the forecast period. The rise in chronic diseases around the globe, which is influencing the demand for immune health supplements. In addition, rising demand for the immune health supplements coupled with changing lifestyles of consumers across global, which is also estimated to fuel the global immune health supplements market growth in a positive way. Increased investments in R&D are driving the global immune health supplements market growth in a positive way. However, lack of awareness regarding immune health supplements among consumers is expected to hamper the global immune health supplements market growth in the forecast period.
COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025
The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the COVID vaccines market is attributed majorly to the rising number of people infected with COVID-19 and increasing funding for vaccine development.
On the other hand, the global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, and the emergence of alternative therapies such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1. Moreover, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies are fueling the market growth.
Currently, the R&D landscape for COVID-19 vaccines includes 115 vaccine candidates. The most advanced candidates that have recently moved into clinical development are:
- mRNA-1273 from Moderna
- Ad5-nCoV from CanSino Biologics
- INO-4800 from Inovio
- LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute
VACCINE MANUFACTURING RAMP-UP TO DRIVE THE GROWTH FURTHER
Currently, around 155 molecules are under clinical investigation, and about 45 molecules are under preclinical development to be targeted against COVID-19. In this list, four promising drugs have been repurposed for use against COVID-19.
Chloroquine and hydroxychloroquine
Lopinavir and ritonavir (and that same combination plus interferon-beta)
An immune system messenger that can help stop the multiplication of viruses.
CALL FOR SUBMISSIONS
Abstracts will be reviewed by the Abstract Review Board (ARB) of the conference
- Immunity Basic and Clinical Aspects
- Covid- 19 and Immunity
- Behavioural Immune System
- Covid-19 detection by immunochemistry
- Viral Immunology and Vaccines Development
- Immune System and Antibodies response
- Allergies and Hypersensitivity
- Autoimmune diseases and Immunodeficiency
- Cancer Immunology and Immunotherapy
- Innate and Adaptive Immunity
- Immunoinformatic and Systems Immunology
- Immunogenicity and Immunotoxicology
- Cytokine and T Cell-Based Immunotherapy
- Immune Regulation and Inflammation
- Immune Mechanisms of Human Disease
- Anti-Immune Strategies to Pathogen Control and Evasion
- Structural and Cellular Aspects of Innate Lymphocytes
- Interventions and Monitoring in Vaccination
- Effect of Nutrition in Immunity and Metabolism
- Traditional Alternative Medicine in boosting Immune System
- Gene-editing in Immune cell therapies
Andrea NicoliniClinical ResearcherUniversity of Pisa, Italy
BIOGRAPHYDr. Nicolini graduated (summa cum laude) at School of Medicine, University of Pisa in 1974. He received postgraduate diplomas at University of Pisa in Internal Medicine (1980), Pneumology (1984), and Nuclear Medicine (1986). His research interests include breast and gastrointestinal cancer and their metastases, tumour markers, post-operative follow-up, physiopathology, immunology and immunotherapy of cancer, and thyroid tumours.RESEARCHES :breast and gastrointestinal cancerLyudmyla SymochkoAssociate ProfessorInstitute of Agroecology and Environmental ManagementUzhhorod National University, Ukraine
BIOGRAPHYSymochko Lyudmya is a specialist in environmental microbiology and soil ecology. Since 2008 she has focused on autecology and synecology researches of soil microbiota. She explores the soil resistome and the role of natural and transformed ecosystems as reserves of antibiotic-resistant microorganisms. She developing and improving existing methods of bioindication and biotesting the edaphotops in different biogeocenosis. She is an author of over 120 scientific publications and 55 in professional journals.RESEARCHES :soil resistome and human healthAhmed HegaziProfessorMicrobiology and ImmunologyNational Research Center, Egypt
BIOGRAPHYAhmed Hegazi is currently a Professor of Microbiology and Immunology in the National Research Center, Egypt. Prof. Hegazi received his master’s degree in 1979 and his PhD in 1981. Hegazi’s research work has been focused lately on bee products and their therapeutic effects. Hegazi organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 222 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA).RESEARCHES :Prof. Hegazi’s research work has been focused lately on bee products and their therapeutic effects.Aaron LernerProfessorAesku.Kipp Institute. Wendelsheim, Germany
BIOGRAPHYAfter receiving his MD from the Sakler school of medicine, Tel-Aviv University (1976), Professor Lerner specialized in Pediatrics ( 1982 ), Pediatric Gastroenterology and Nutrition ( 1984 ) and Adult Gastroenterology ( 1987). Took several senior positions as head of Department of pediatrics (1995-2005) and head of Pediatric Gastroenterology and Nutrition unit, at the Carmel Medical Center, Haifa, Israel. Finished his Medical Management degree M.H.A, at Ben- Gurion University, Beer-Sheba, Israel (1999), spent research sabbaticals in Hahnemann University, Philadelphia, PA, USA (1991), State University of North Carolina, Chapel Hill, N.C, U.S.A (2005) and currently, involved In scientific projects in Aesku.Kipp Institute, Wendelsheim, Germany.(2014-2020). RESEARCHES :pathogenesis, diagnosis and treatment of systemic autoimmune diseases (ADs) in particular gastrointestinal conditions and pediatric nutrition, nutritional assessment and deficiencies, celiac and Crohn’s diseasesGisele PicoloDirectorLaboratory of Pain and SignalingButantan Institute, São Paulo, Brazil
BIOGRAPHYGisele Picolo graduated in Biology, obtained her master degree in Experimental and Comparative Pathology and her PhD in the field of Pharmacology. She is currently researcher at Butantan Institute and Director of the Laboratory of Pain and Signaling. She acts as principal investigator at the Center for toxins, immune response and cell signaling (CeTICS, Brazil) and as a collaborative researcher at the Center of excellence in the discovery of new molecular targets (CENTD, Brazil). She acts in the areas of Pathophysiology and Pharmacology, acting mainly on the following themes: pain and inflammation, analgesia, animal poisons and toxins, and in the search for new analgesic compounds. She was awarded with the IASP Developing Countries Collaborative Research Grants, offered by the International Association for the Study of Pain in 2016, and awarded among the 5 best works in chronic pain during the 6th International Congress on Neuropathic Pain, Sweden, 2017. She is member of the National Commission for the Organization of the Brazilian Biology Olympics since 2018. She authored more than 45 publications (scientific articles, reviews, monographs, book chapters). She has 4 patents applied as inventor in the area of analgesics.RESEARCHES :Pathophysiology and Pharmacology
OUR COLLABORATIONS, SPONSORS, MEDIA PARTNERS
about:blankImagemEnvie uma imagem, escolha uma da sua biblioteca de mídia ou adicione um URL.EnviarSelecionar imagemInserir a partir de um URL
Select country Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Canadian Nunavut Territory Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling Islands) Colombia Comoros Congo Cook Islands Costa Rica Cote D’Ivoire (Ivory Coast) Croatia (Hrvatska) Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France France, Metropolitan French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea (North) Korea (South) Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda S. Georgia and S. Sandwich Isls. Saint Kitts and Nevis Saint Lucia Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovak Republic Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka St. Helena St. Pierre and Miquelon Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu US Minor Outlying Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu United States United Kingdom Vatican City State (Holy See) Venezuela Viet Nam Virgin Islands (British) Wallis and Futuna Islands Western Sahara Yemen Yugoslavia Zaire Zambia Zimbabwe https://www.google.com/recaptcha/api2/anchor?ar=1&k=6LeJSHMUAAAAAO-QzUSgqSnq4j5FXU5-6kLPbclK&co=aHR0cHM6Ly93d3cubGV4aXNtZWV0aW5nLmNvbTo0NDM.&hl=pt-BR&v=pRiAUlKgZOMcFLsfzZTeGtOA&size=normal&cb=u57wziuvw4or
Conference Inquiries : email@example.com
Contact Address :Avenue Roger Vandendriessche 18, 1150 Brussels, Belgium
Toll Free +32 (800) 753-58
+44 (203) 966-4288
© 2020 LexisMeetings, All Rights Reserved.about:blank
Status e visibilidade
VisibilidadePúblicoPublicar19 Feb 2021 11:41Fixar no topo do blogHabilitar AMPMover para a lixeira25 revisões
Sem categoriaAdicionar nova categoria
Imagem de destaque
É recomendado selecionar uma imagem destacada para uma melhor experiência do usuário.Definir imagem destacadaSelecionar imagem
Abrir o painel de publicação
RECENTThe Diminishing Role of Operating Systems JAN 06, 2021Red Hat Opens the Door for Windows Containers in OpenShift JAN 06, 2021
10 Cybersecurity Threats Enterprise IT Should Watch Out for in 2021 JAN 05, 2021Slack Service Disrupted as People Return to Work After Holidays JAN 04, 2021The List of Known SolarWinds Breach Victims Grows, as Do Attack Vectors DEC 23, 2020FEATUREDData Center and IT Trends to Watch in 2021 OCT 01, 2020What Data Center Colocation Is Today, and Why It’s Changed NOV 16, 2020Everything You Need to Know About Colocation Pricing NOV 13, 2020Why Equinix Doesn’t Think Its Bare Metal Service Competes With Its Cloud-Provider Customers NOV 09, 2020RIKEN Center for Computational ScienceArm-powered Fugaku, in Kobe, Japan, is the the world’s fastest supercomputer as of November 2020, according to Top500.org.DESIGN>SUPERCOMPUTERS
Top500: Japan’s Fugaku Still the World’s Fastest Supercomputer
Growth of the cumulative computing power of Top500 systems is slowing down, pushing Moore’s Law closer to obsolescence.
Scott Fulton III | Nov 18, 2020
Fugaku, the Japanese computing cluster that won the Top500 race of the world’s fastest supercomputers earlier this year has taken the gold medal in the biannual contest again. This time around, it’s extended its lead over the rest of the field.
The system, built by Fujitsu for Japan’s RIKEN Center for Computational Science, posted a maximum sustained performance level of 442,010 teraflops per second on the Linpack benchmark. The non-profit Top500 organization released its November 2020 results this week.
That’s a 6.4 percent speed improvement over Fugaku’s score on the same test, posted last June. During the official announcement of the results Monday, RIKEN’s director, Satoshi Matsuoka, attributed the improvement to finally being able to use the entire machine rather than just a good chunk of it. The November 2020 Top500 list shows that the machine’s core count has increased by about 330,000 – the equivalent of about 6,912 additional Fujitsu Arm A64FX processors.
Looks Like a Butterfly…
RIKEN couldn’t use the system’s full power for the June competition because his team simply didn’t have enough time, Matsuoka explained. “We only had two weeks to the deadline from the time we brought up the final nodes of the machine. . . We had very little time, and a lot of benchmarks had been compromised.”
Since then, his team had ample opportunity not only to bring up the remaining nodes in the full cluster but also to fine-tune the code for maximum performance.
“I don’t think we can improve much anymore,” he said.
Fugaku scored what the supercomputing industry now calls a “triple,” scoring first on the accompanying HPCG and HPL-AI benchmark tests. HPCG provides what long-time Top500 co-maintainer Martin Meuer called “another angle into the hardware,” giving more favorable scores to systems that are tuned for efficiency and control of memory bandwidth, for instance. HPL-AI is a much faster running test, trading high-precision floating-point operations for lower-precision math more commonly used in machine learning — for example, for training convolutional neural networks.
Fugaku is one of only two systems in the Top500 with custom processing architectures. The other is Sunway TaihuLight, in fourth place this time around but previously the champion for two consecutive years, built for China’s National Supercomputing Center in Jiangsu province.
…Stings Like a Bee
Fugaku’s extended performance lead represents even more success for Arm architectures, which have been receiving much greater scrutiny now that the physical barriers of Moore’s Law appear to have been reached. We asked Matsuoka whether there are any lessons to be learned from Fujitsu’s development of its own supercomputer-exclusive processors that can explain why Fugaku continues to enjoy such a performance advantage over x86-based systems on the list?
Lesson number one, he told DCK, was the importance of co-design. “When, globally, we embarked on this endeavor of trying to reach exascale [1 exaflop per second and beyond], the emphasis was not just placed on achieving exascale, but really to excel in application performance.
Analyzing what it would take to reach that goal with the technology available in 2020, his team concluded that it wouldn’t be possible with off-the-shelf chips. “We had to rethink what we would do,” he said.
At that time, the eventual co-designers of A64FX determined that, at its current growth trajectory, memory bandwidth available to x86 server-class CPUs would touch 200GB/s (gigabyte per second). For the applications RIKEN was planning, they would need 1 TB/s. Soon, AMD, Samsung, and SK Hynix started collaborating on High-Bandwidth Memory (HBM), in which bandwidth could be increased by stacking DRAM modules atop one another. That might score some points with cloud or enterprise server manufacturers, but he said HBM would cause issues with respect to cache hierarchies and chip interconnects — factors that would have been detrimental to the deterministic performance that HPC components require.
“It was very important to think about what would be your objective, what would be the target, and really start from a clean slate,” RIKEN’s leader told us. “Think about whether your goal would be met by off-the-shelf processors, or you’d really have to invent your own. In our case, it was the latter.”
The Moore’s Law Pitfall
Up until a few years ago, supercomputer operators looked to Moore’s Law to provide a rough estimate (the doubling of compute capacity in new systems every 18 months) of how long they should expect to operate the machines they have before taking the plunge and investing in new ones. Specialists know how much power they’ll need from their machines to solve particular problems, and Moore’s Law projected when machines would become available that could deliver such power, if they didn’t have it at the time.
Earlier this week, during the Supercomputing 2020 conference (this year held online), Berkeley National Labs’ Erich Strohmaier presented a chart clearly depicting the chughole left open by the decline of Moore’s Law. Since the list was first kept in 1994 up until 2013, according to this chart, performance growth among all machines in the Top500 grew in fits and starts, averaging out to 180 percent annually, or 1000x over an 11-year period. The saw-toothed line during this period could be attributed to the famous “tick-tock” cadence of Intel’s innovation agenda. During this phase, Intel tended to represent the lion’s share of CPUs in supercomputers, although there were years when AMD was competitive.
In 2013, said Strohmaier, there was a significant downturn in the global economy, which prompted research institutions to extend their investments in existing systems, postponing their planned replacements by at least two years. At this point, annual growth stumbled to an average of about 140 percent annually, even though the economy was in recovery up until the pandemic.
“After June 2013, all segments in the Top500 basically slowed down to the new growth rates,” said Strohmaier. “Those rates are substantially lower than before. . . If you multiply that out, it now takes about 20 years for an increase of 1000x.”
The pace of commercial HPC owners replacing their systems, already slowed by the previous economic slowdown and the erosion of Moore’s Law, was only deepened by the pandemic, Strohmaier reported. Since 2013, the semi-annual replacement count for commercial systems had stayed roughly the same but plunged below the number of academic systems replaced.
“If anything, in 2020, the number of new systems in research centers has actually slightly increased,” he said. “Business as usual. The research centers have not delayed any purchases or installations in large numbers due to COVID. That has not happened.”
The pandemic may only have served to dampen what was already cooling enthusiasm for high-performance computing among commercial operators, including interest in GPU accelerators and other new architectures. Among the top 50 systems on the list, 17 still do not use accelerators at all. Another one-third use Nvidia-brand GPU accelerators, while the remainder use other types, such as FPGA or Intel Xeon Phi.
Among the top 100 systems on the list, about half of academic and half of commercial systems are powered by Intel’s x86 processors (not AMD’s) without any accelerators at all. It’s astonishing, Strohmaier said, that accelerators haven’t permeated the academic market anywhere near the extent predicted. Of the commercial systems in the top 100, about 80 percent use Nvidia-brand accelerators.
This is resulting not just in a mix of systems across operator classes, but a kind of settling of those classes into their own peculiar profiles.
“Research institutions are much more willing to adopt new technologies, to try out new things, and to go with architectures that are not as common in the market.” For example, IBM Power AC922 systems coupled with Nvidia GPUs (eight of the current Top500 systems), AMD-based systems (24 of 500), and Arm-based systems (three of 500).TAGS: DESIGNHARDWAREARM0 COMMENTSRECOMMENDED READINGAfter Moore’s Law: How Will We Know How Much Faster Computers Can Go?DEC 21, 2020Why the Supercomputer Sector May Bifurcate – AgainDEC 03, 2020Nvidia Offers UK Covid Supercomputer While Waiting on Arm DealOCT 05, 2020Fujitsu’s Arm-Powered Supercomputer Beats US, China to Take World Speed CrownJUN 23, 2020
- CCPA: Do not sell my personal info
- Terms of Service
- Content Licensing/Reprints
© 2021 Informa USA, Inc., All rights reserved
- SciTech: ReimaginedHAVE YOU REGISTERED?
- 2021 Propulsion & Energy Forum Call for PapersNOW OPEN
- Maximize Your Membership: Update Your Profile & Professional Interest CodesCOUNT ME IN
Helping aerospace professionals and their organizations succeed. JOIN AIAA
- AIAA Recognizes Excellence in Aerospace with Awards to be Presented During the 2021 AIAA SciTech Forum6 JANUARY 2021READ MORE
- 2021 AIAA SciTech Forum Features Free Program Honoring Dr. Martin Luther King Jr.5 JANUARY 2021READ MORE
- AIAA Statement on FY2021 National Defense Authorization Act1 JANUARY 2021READ MORE
Find premiere aerospace technology, engineering, and science content and research across 100+ topics.
Connect with all of your AIAA colleagues online. Find your community and join the conversation.
Support the next generation of aerospace professionals through innovative educational programs and recognition.
Search a list of businesses and contacts in the astronautical and aeronautical industries.
American Institute of Aeronautics and Astronautics
12700 Sunrise Valley Drive, Suite 200
Reston, VA 20191-5807
© 2020 American Institute of Aeronautics and Astronautics